The Vitamin Nobody Talks About — But Should
Vitamin K exists in two main families: K1 (phylloquinone), found abundantly in leafy greens and primarily involved in blood clotting, and K2 (menaquinones), a group of fat-soluble compounds found in fermented foods and animal products that play an entirely different — and arguably more consequential — role in cardiovascular and skeletal health.
The confusion between K1 and K2 is not semantic. For decades, nutrition research lumped the two together, which led to the erroneous conclusion that most people got enough vitamin K from their diet. They were measuring K1 — the clotting vitamin — while K2, the calcium traffic controller, remained almost entirely unstudied and underappreciated.
The consequences are visible in modern epidemiology: populations with adequate calcium intake but insufficient K2 show paradoxical patterns of simultaneously losing bone mass while accumulating arterial plaque. This is the calcium paradox, and understanding it begins with understanding exactly what K2 does at the molecular level.
Key insight: Vitamin K2 does not compete with K1 for function. K1 handles coagulation; K2 handles calcium regulation. You can have perfect K1 status and still be functionally K2-deficient — most people in Western populations are.
Forms, Nomenclature, and Why MK-4 vs MK-7 Matters
Menaquinones are named by the length of their isoprenoid side chain — MK-4 through MK-13. In supplementation and clinical research, two forms dominate: MK-4 (menatetrenone) and MK-7 (menaquinone-7). The difference in chain length is not cosmetic — it fundamentally changes pharmacokinetics, tissue distribution, and practical utility.
MK-4 has four isoprenyl units in its side chain. It is found in animal-derived foods including egg yolks, butter, goose liver, and organ meats. MK-4 is also the form produced endogenously when the body converts K1 in peripheral tissues. Its half-life is approximately 1 to 2 hours, which means it clears rapidly from blood. Studies using MK-4 typically employ pharmacological doses (45 mg/day) to achieve the tissue accumulation needed for clinical effect — particularly in Japanese research on bone density and fracture prevention.
MK-7 has seven isoprenyl units, making it significantly more lipophilic. This structural feature extends its half-life to approximately 48–72 hours and produces much higher and more sustained serum concentrations at relatively low doses (90–200 mcg/day). MK-7 is primarily found in natto — Japanese fermented soybeans — and to a lesser extent in other fermented foods. Because of its longer residence time in circulation, MK-7 is superior for the continuous carboxylation of extrahepatic Gla proteins, particularly matrix Gla protein in vascular smooth muscle cells.
Carboxylation: The Molecular Switch That Determines Where Calcium Goes
To understand Vitamin K2's function, you must first understand the carboxylation reaction it enables. Vitamin K2 acts as an essential cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which converts specific glutamic acid residues in target proteins into gamma-carboxyglutamic acid (Gla) residues. This chemical modification — carboxylation — fundamentally changes the protein's structure: it gains the ability to bind calcium ions with high affinity.
Without adequate Vitamin K2, GGCX cannot function, the target proteins remain undercarboxylated (uc- prefix in lab notation), and they lose their calcium-binding capacity entirely. This is not a partial impairment — it is a binary switch. Undercarboxylated matrix Gla protein cannot bind calcium; carboxylated matrix Gla protein binds it avidly.
The Two Proteins at the Center of the Calcium Paradox
Matrix Gla Protein (MGP) is produced by vascular smooth muscle cells and chondrocytes. When fully carboxylated by K2, MGP is arguably the most potent known inhibitor of vascular calcification. It accomplishes this through two mechanisms: direct inhibition of calcium crystal nucleation in vessel walls, and inhibition of bone morphogenetic protein-2 (BMP-2), a signaling molecule that promotes osteoblastic differentiation in smooth muscle cells — essentially preventing arteries from beginning to behave like bone tissue.
In K2 deficiency, ucMGP accumulates in arterial walls. Circulating ucMGP can now be measured via blood test and serves as a biomarker of both K2 insufficiency and cardiovascular risk. Studies have shown that high ucMGP concentrations predict increased arterial stiffness, coronary calcification, and adverse cardiovascular outcomes independently of traditional risk factors.
Osteocalcin is produced by osteoblasts (bone-building cells) and is the most abundant non-collagen protein in bone matrix. When carboxylated by K2, osteocalcin anchors calcium and hydroxyapatite crystals into the bone matrix — a process essential for proper bone mineralization and tensile strength. Undercarboxylated osteocalcin (ucOC) is a validated marker of K2 insufficiency and is independently associated with fracture risk. High serum ucOC levels indicate that osteoblasts are producing osteocalcin, but K2 is insufficient to activate it — the protein is present but functionless.
Clinical note: Both ucMGP and ucOC can be measured via standard laboratory testing and provide far more actionable information about K2 status than serum K2 levels alone. If you are optimizing for cardiovascular or bone health, these biomarkers are worth tracking.
The Cycle of K2 Regeneration
During carboxylation, Vitamin K2 is oxidized to Vitamin K 2,3-epoxide. Normally, an enzyme called Vitamin K epoxide reductase (VKORC1) converts this epoxide back to the active form — completing what is called the Vitamin K cycle. This recycling mechanism is the very target of warfarin (see below), and its disruption has downstream consequences not just for clotting factor activation (the intended warfarin effect) but also for MGP and osteocalcin carboxylation throughout the body.
The Rotterdam Study: Population Evidence for K2's Cardiovascular Role
The most influential epidemiological evidence for Vitamin K2's cardiovascular benefit comes from the Rotterdam Study — a large prospective cohort study conducted in the Netherlands that began in 1990 and has followed over 14,000 participants. The K2-specific findings were published in 2004 by Geleijnse et al. in the Journal of Nutrition and remain one of the most cited studies in micronutrient cardiovascular research.
The researchers analyzed dietary intake data from 4,807 participants with no prior history of myocardial infarction, followed for approximately 7–10 years. They examined the association between dietary intake of Vitamin K1 and Vitamin K2 (measured as total menaquinone intake, primarily MK-4 through MK-10) and cardiovascular outcomes.
What the Data Showed
The findings were striking and specific to K2 — K1 showed no significant cardiovascular associations. Participants in the highest tertile of dietary K2 intake compared to the lowest showed:
- A 57% lower risk of aortic calcification (as assessed by X-ray)
- A 52% lower risk of dying from coronary heart disease
- A 41% lower risk of coronary heart disease events
- A 26% lower risk of all-cause mortality
These associations remained significant after adjustment for age, sex, BMI, smoking, diabetes, systolic blood pressure, cholesterol, and dietary factors. The effect size — particularly the 57% reduction in aortic calcification — was substantial enough to generate significant research interest and catalyze subsequent interventional trials.
Important context: The Rotterdam Study is observational — it demonstrates association, not causation. Diet is notoriously difficult to measure accurately, and confounding is always possible in dietary studies. That said, the biological mechanism (MGP carboxylation) is established from biochemical research, which lends the epidemiological association mechanistic plausibility. The association is not a coincidence — it has a known molecular explanation.
Follow-Up Research and Interventional Trials
The Rotterdam Study prompted several follow-up investigations. The Prospect-EPIC cohort (16,057 women, Netherlands) found that for every 10 mcg increase in dietary K2 intake, coronary heart disease risk fell by 9%. Notably again, K1 showed no association.
Interventional trials have examined K2's effect on arterial stiffness. A 2015 randomized controlled trial by Knapen et al. published in Thrombosis and Haemostasis found that daily supplementation with 180 mcg of MK-7 for three years significantly reduced arterial stiffness — measured by pulse wave velocity — in healthy postmenopausal women, with more pronounced effects in women with initially higher arterial stiffness. The effect was not seen in the placebo group.
The Calcium Paradox: How You Can Calcify Your Arteries While Losing Bone
The calcium paradox is one of the most practically important concepts in modern nutritional medicine, yet it remains poorly understood by most clinicians and patients. The paradox refers to this simultaneous reality observed in many aging adults and calcium-supplementing populations: osteoporosis and arterial calcification occurring at the same time in the same body.
For decades, the clinical response to osteoporosis was to recommend calcium supplementation — a seemingly logical approach. More calcium in the diet, the thinking went, means more calcium available for bones. The results were problematic. Meta-analyses, including a controversial but influential 2010 analysis by Bolland et al. in the British Medical Journal, found that calcium supplementation without co-factors was associated with increased risk of myocardial infarction. The calcium was going somewhere — just not primarily to bones.
Why Calcium Ends Up in the Wrong Place
The answer lies in transport biology and carboxylation status. When calcium is absorbed from the gut (a process facilitated by Vitamin D3), it enters the bloodstream and must be directed to the appropriate tissues. In the presence of fully carboxylated MGP in arterial walls, calcium cannot nucleate there — the protein actively repels calcium crystal formation. In the presence of carboxylated osteocalcin in bone, calcium is actively captured and incorporated into the hydroxyapatite matrix.
In K2 insufficiency, this directional guidance breaks down entirely. ucMGP cannot inhibit vascular calcification, and ucOC cannot capture calcium for bone. The calcium circulates, and wherever conditions favor precipitation — which in arterial walls chronically exposed to oxidative stress and inflammation is readily — it deposits. Simultaneously, bone fails to mineralize properly because osteocalcin, despite being present, cannot do its job.
This is not a calcium problem. It is a K2 problem. The calcium is there; the delivery system is broken.
The Fermented Food Evidence
The population-level evidence for this mechanism is perhaps most dramatic when comparing Japan to Western nations. Japanese men and women — particularly in regions where natto (fermented soybeans, exceptionally high in MK-7) is consumed regularly — show dramatically lower rates of hip fracture and cardiovascular calcification compared to age-matched Western cohorts despite similar or lower calcium intakes. A 2006 study found that prefectures in Japan with higher natto consumption had significantly lower hip fracture rates in women, even after controlling for regional dietary differences.
This is not a calcium intake story. Japan does not have particularly high calcium intake. It is a K2 story — specifically, MK-7 from natto maintaining carboxylation of both MGP and osteocalcin throughout adult life.
Warfarin, Anticoagulants, and the K2 Antagonism Problem
Warfarin (Coumadin) is a Vitamin K antagonist — it works by inhibiting VKORC1, the enzyme responsible for regenerating active Vitamin K from its epoxide form. By blocking this recycling enzyme, warfarin depletes active Vitamin K and impairs carboxylation of clotting factors II, VII, IX, and X, thus reducing the blood's clotting capacity.
The anticoagulant effect is intentional and clinically important — it is why warfarin is prescribed for atrial fibrillation, deep vein thrombosis, and mechanical heart valves. The collateral damage to MGP and osteocalcin carboxylation is not.
The Irony of Warfarin and Cardiovascular Calcification
Here lies a profound clinical irony: warfarin, prescribed in many cases to reduce cardiovascular risk (specifically thrombotic events), simultaneously impairs the one protein most responsible for preventing arterial calcification. Studies in patients on long-term warfarin therapy have found significantly elevated ucMGP levels, increased aortic calcification scores, and greater arterial stiffness compared to age-matched controls not on anticoagulation.
A 2012 study published in Blood demonstrated that warfarin use was associated with increased coronary and aortic calcification independent of underlying disease. In patients treated with warfarin for more than three years, coronary calcification scores were significantly higher than in those not on the medication.
Critical warning: If you are currently prescribed warfarin or any Vitamin K antagonist anticoagulant, do NOT supplement with Vitamin K2 without explicit guidance from your prescribing physician. Even small amounts of K2 can alter INR (international normalized ratio) and affect anticoagulation safety. This is a serious drug-nutrient interaction requiring medical supervision.
Newer Anticoagulants (DOACs) and K2
The newer class of direct oral anticoagulants (DOACs) — rivaroxaban, apixaban, dabigatran, edoxaban — work by different mechanisms (direct Factor Xa or thrombin inhibition) and do not act as Vitamin K antagonists. They therefore do not impair K2-dependent carboxylation of MGP or osteocalcin. Patients on DOACs can generally supplement K2 without altering the anticoagulant effect, though consulting a physician before adding any supplement is always advisable.
Vitamin D3 and K2 Synergy: Why You Cannot Have One Without the Other
The relationship between Vitamin D3 and Vitamin K2 is one of the most clinically important nutrient synergies in human physiology — and one of the most commonly misunderstood. They do not simply "work together." They are part of the same cascade, and supplementing one without the other can actively create problems.
How D3 Drives K2 Demand
Vitamin D3 (cholecalciferol), once converted to its active form 1,25-dihydroxyvitamin D3 (calcitriol) via liver and kidney hydroxylation, functions as a steroid hormone that binds nuclear Vitamin D receptors (VDR) throughout the body. One of calcitriol's most important genomic actions is the upregulation of osteocalcin gene expression in osteoblasts — it directly increases the production of osteocalcin protein.
Simultaneously, D3 upregulates intestinal calcium absorption and promotes calcium entry into the bloodstream. This means that increasing D3 status simultaneously raises circulating calcium and increases the production of osteocalcin — the protein that needs K2 to be activated. If K2 is insufficient, the extra osteocalcin produced under D3 stimulation remains undercarboxylated and cannot capture calcium. The D3-absorbed calcium has nowhere to go in bone — and may instead deposit in soft tissue.
This is the mechanism behind the concern that high-dose D3 supplementation without K2 co-supplementation may paradoxically increase soft tissue calcification risk. The evidence for this specific harm is not definitively established in clinical trials, but the mechanistic logic is compelling and forms the basis for widespread clinical recommendations to combine the two.
D3 Also Upregulates MGP
Vitamin D3 also increases the transcription of MGP in vascular smooth muscle cells. Again, more MGP production under D3 stimulation means greater K2 demand to carboxylate all that extra protein. The system is coherent: D3 expands capacity; K2 activates it. Neither nutrient alone optimally fulfills the biological goal.
Recommended Ratios and Practical Dosing
Most functional medicine clinicians and the research supporting combined supplementation suggest pairing Vitamin D3 with MK-7 Vitamin K2 at a ratio of roughly 2,000–5,000 IU D3 with 100–200 mcg MK-7. Some practitioners use higher D3 doses for deficiency correction (up to 10,000 IU), in which case K2 doses at the higher end of the range (200–300 mcg) may be appropriate. Both are fat-soluble and should be taken with a meal containing dietary fat for optimal absorption.
K2 Forms Comparison: Evidence at a Glance
| K2 Form | Half-Life | Bioavailability | Best Use | Key Study |
|---|---|---|---|---|
| MK-4 | 1–2 hours | Moderate; requires higher doses for sustained tissue levels | Bone density (pharmacological doses: 45 mg/day in Japanese fracture studies) | Shiraki et al. (2000): 45 mg/day MK-4 reduced fracture incidence in osteoporotic women |
| MK-7 | 48–72 hours | High; sustains serum levels at doses as low as 90 mcg/day | Cardiovascular protection, ongoing MGP carboxylation, once-daily dosing | Knapen et al. (2015): 180 mcg/day MK-7 reduced arterial stiffness over 3 years |
| MK-9 | ~24–48 hours | Lower; less studied; present in some hard cheeses | General menaquinone intake via diet (Gouda, Edam) | Rotterdam Study (2004): dietary MK-9 among K2 forms associated with reduced CHD |
| MK-4 + MK-7 combo | Blended kinetics | High short-term (MK-4) + sustained (MK-7) | Comprehensive carboxylation coverage; theoretical advantage for both bone and CV endpoints | Combination products gaining research interest; limited head-to-head RCTs to date |
| K1 (phylloquinone) | 1–2 hours | Variable; 10–15% from food | Coagulation factor activation (hepatic); limited extrahepatic Gla protein activation | Rotterdam Study: no significant association between K1 intake and CVD outcomes |
Fermented Food Sources and Dietary K2 Intake
Dietary Vitamin K2 is concentrated in specific food categories that are largely absent from standard Western diets. Understanding the food sources makes it immediately clear why most Western populations are chronically K2 insufficient.
Natto: The Highest Known Food Source of MK-7
Natto is a traditional Japanese food made by fermenting soybeans with Bacillus subtilis natto. The bacterial fermentation produces extraordinarily high concentrations of MK-7 — a single 100g serving of natto contains approximately 1,000–1,100 mcg of MK-7. This is an order of magnitude above any other known food source. Regular natto consumption (even 30–50g portions several times per week) provides more than sufficient MK-7 for complete MGP and osteocalcin carboxylation.
For those who find natto's texture and strong flavor challenging, the alternative is supplementation with MK-7 extracted via fermentation of B. subtilis natto — the same bacterially derived form used in virtually all high-quality MK-7 supplements.
European Fermented Cheeses
European hard and semi-hard cheeses — particularly Gouda and Edam — are meaningful sources of dietary menaquinones, primarily in the MK-8 and MK-9 forms produced by the bacteria used in cheese aging. These longer-chain menaquinones have intermediate half-lives and contribute to dietary K2 intake in European populations. This may partially explain why Dutch participants in the Rotterdam Study showed some of the highest dietary K2 intakes outside of Japan — their traditional diet is cheese-heavy.
Other Animal-Derived Sources (Primarily MK-4)
Animal products contain MK-4, derived partly from dietary conversion of K1. Sources include goose liver (the richest animal source at ~370 mcg per 100g), duck liver, chicken liver, egg yolks (from pasture-raised hens significantly higher than conventionally raised), butter from grass-fed cows, and some cuts of organ meat. Factory-farmed animals on grain-based diets have substantially lower K2 content than pasture-raised counterparts — their diet limits the K1 available for enzymatic conversion to MK-4.
Vitamin K2 MK-7 Supplement (90–200 mcg)
Look for fermentation-derived MK-7 in a softgel or oil-based capsule for optimal fat-soluble absorption. Third-party tested brands with at least 90 mcg MK-7 per serving are the most validated by clinical research.
🛒 Shop MK-7 on AmazonAffiliate link — StackProtocol earns a commission at no extra cost to you. Always check with your healthcare provider before starting new supplements.
Vitamin D3 + K2 Combination Supplement
Pre-formulated D3+K2 combinations ensure you never take one without the other. Look for 2,000–5,000 IU D3 paired with 100–200 mcg MK-7, in an oil-based carrier (MCT, olive oil, or sunflower oil) for best absorption.
🛒 Shop D3+K2 Combo on AmazonAffiliate link — StackProtocol earns a commission at no extra cost to you. Consult your physician before supplementing, especially if you take blood thinners.
Your Action Plan: A Clinical-Grade K2 Protocol
The K2 Optimization Stack Protocol
- Get baseline labs first. Request ucMGP (undercarboxylated matrix Gla protein) and ucOC (undercarboxylated osteocalcin) to quantify your actual K2 functional status. Serum K2 levels are not sufficient — functional biomarkers are what matter. Also check 25-OH Vitamin D and calcium while you are at it.
- Choose MK-7 as your primary K2 form. For cardiovascular and extrahepatic Gla protein carboxylation, MK-7 at 100–200 mcg daily is the form with the best evidence base and the most practical pharmacokinetics. If bone health is a primary concern alongside cardiovascular protection, some practitioners add a modest MK-4 dose (1–5 mg) for tissue-specific activity.
- Always combine with Vitamin D3. Start at 2,000–5,000 IU D3 daily (depending on baseline serum 25-OH-D). Higher deficiency correction doses (5,000–10,000 IU) should be monitored with quarterly 25-OH-D testing. Dose K2 proportionally higher when D3 dose is higher.
- Take both with fat. Vitamin K2 and D3 are fat-soluble. Absorption improves substantially when taken with a meal containing dietary fat — even a tablespoon of olive oil or a handful of nuts with your supplement is sufficient. Emulsified or oil-based softgel formulations offer somewhat better absorption than dry powder capsules.
- Increase dietary fermented foods. Even modest natto consumption (30g several times weekly) or regular consumption of aged European cheeses contributes meaningful dietary K2 and reduces reliance on supplementation alone. Dietary forms come in a matrix of co-factors that may not be fully replicated in isolation.
- Check for drug interactions. If you take warfarin, coumadin, or any Vitamin K antagonist — stop here and consult your physician before proceeding. If you take DOACs (apixaban, rivaroxaban, dabigatran), K2 supplementation is generally safe but confirm with your prescribing doctor.
- Consider magnesium and Vitamin A as co-factors. Magnesium is required for Vitamin D3 activation (kidney hydroxylation step) and is itself commonly deficient. Vitamin A (retinol) works in concert with D3 and K2 in the regulation of osteocalcin and other Gla proteins. A comprehensive fat-soluble vitamin approach includes all four: A, D3, K2, and adequate dietary magnesium.
- Re-test at 3–6 months. Recheck ucMGP, ucOC, and 25-OH-D after 3–6 months of consistent supplementation. The goal is near-complete carboxylation — low ucMGP and ucOC with adequate serum D. Adjust doses accordingly based on lab response, not on a fixed protocol alone.
Common Questions: K2 Science Unpacked
Can I get enough K2 from diet alone without supplements?
If you regularly eat natto (even 30–50g several times a week), the answer is almost certainly yes — natto's MK-7 content is so high that modest consumption fully covers carboxylation needs. If you eat substantial amounts of high-quality animal products from pasture-raised animals (liver, egg yolks, butter), you likely get meaningful MK-4. For most people eating a standard Western diet without natto or organ meats, supplementation is practically necessary to achieve the MK-7 blood levels associated with cardiovascular benefit in the interventional literature.
Is there any toxicity risk with K2?
Vitamin K2 has an extremely favorable safety profile in the absence of anticoagulant use. Unlike the fat-soluble vitamins A and D, K2 does not accumulate to toxic levels in standard supplementation ranges. There is no established upper tolerable intake level for K2 because toxicity has not been observed at clinical doses. Adverse effects in healthy, non-anticoagulated individuals at doses of 100–300 mcg MK-7 daily are not documented in the literature.
Does K2 directly treat or reverse arterial calcification?
The current evidence is strongest for K2's role in preventing progression of arterial calcification, rather than reversing established calcium deposits. The Knapen 2015 trial showed prevention of stiffness progression in women with existing subclinical stiffness, but did not show active regression of calcification. Some preclinical data in rats suggests that high-dose K2 can activate the protein fetuin-A-based calcification regression pathway, but this has not been demonstrated in controlled human trials. The practical takeaway: start K2 early, before significant calcification develops.
Should I supplement K2 if I already eat a healthy diet with plenty of vegetables?
Yes, likely. Vegetables are high in K1, not K2. A diet rich in leafy greens will optimize your K1 status and clotting factor carboxylation, but will not significantly raise serum MK-7 or carboxylate extrahepatic Gla proteins like MGP. The two forms address entirely different biological functions and dietary K1 richness does not substitute for K2 adequacy.